798
Views
0
CrossRef citations to date
0
Altmetric
Cardiovascular

Management of patient with heart failure: Italian “field practice” experience of sacubitril/valsartan

References

  • Inamdar AA, Inamdar AC. Heart failure: diagnosis, management and utilization. JCM. 2016;5:62.
  • Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1–194.
  • Latini R, Masson S, Staszewsky L. Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook. Expert Rev Cardiovasc Ther. 2016;14:703–711.
  • Iborra-Egea O, Gálvez-Montón C, Roura S, et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl. 2017;3:12.
  • McMurray JJ, Packer M, Desai AS, et al.; PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
  • Sauer A, Cole R, Jensen B, et al. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2019;24:167–176.
  • Pascual-Figal D, Wachter R, Senni M, et al. Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan. ESC Heart Fail. 2018;5:327–336.
  • Velazquez E, Morrow D, DeVore A, et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539–548.
  • Ponikowski P, Voors A, Anker S, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
  • Cameli M, Pastore MC, Pagliaro A, et al. Sacubitril/valsartan in an elderly patient with heart failure: a case report. Cardiology. 2017;138:3–6.
  • Cosentino E. Sacubitril/valsartan in clinical practice: a report of 2 cases. Cardiology. 2017;138:7–10.
  • Sgorbini L, Rossetti A, Galati A. Sacubitril/valsartan: effect on walking test and physical capability. Cardiology. 2017;138:17–20.
  • Monzo L, Lanzillo C, Tota C, et al. Sacubitril/valsartan effect on left ventricular remodeling: the case of a super-responder. Curr Med Res Opin. 2019;1.
  • Severini D, Mboumi K. Sacubitril/valsartan treatment improved the clinical outcome and reduced the hospitalization rate in three patients with chronic heart failure: a case series. Curr Med Res Opin. 2019;1.
  • Pugliese NR, Fabiani I, Zywicki V, et al. Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35%. Curr Med Res Opin. 2019;1.
  • Gubelli S, Caivano M. Case of a patient with heart failure, dilated cardiomyopathy, and atrial fibrillation treated with sacubitril/valsartan. Curr Med Res Opin. 2019;1.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.